{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.889"},{"groupId":"OG001","value":"0.809"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"257"}],"units":"Participants"}],"description":"The Clinical Benefit Rate (CBR) on each treatment arm will be estimated by dividing the number of patients with CR, PR, or SD/Non-CR and Non-PD (for patients with measurable disease) for ≥ 24 weeks by the number of patients randomized to the treatment arm.","groups":[{"description":"Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)","id":"OG000","title":"Arm A"},{"description":"AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)","id":"OG001","title":"Arm B"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Clinical Benefit Rate","type":"SECONDARY","unitOfMeasure":"proportion of participants"}